189 related articles for article (PubMed ID: 21841812)
1. Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.
Bae JW; Choi CI; Kim MJ; Oh DH; Keum SK; Park JI; Kim BH; Bang HK; Oh SG; Kang BS; Park HJ; Kim HD; Ha JH; Shin HJ; Kim YH; Na HS; Chung MW; Jang CG; Lee SY
Acta Pharmacol Sin; 2011 Oct; 32(10):1303-8. PubMed ID: 21841812
[TBL] [Abstract][Full Text] [Related]
2. Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174.
Bae JW; Choi CI; Lee HI; Lee YJ; Jang CG; Lee SY
Int J Clin Pharmacol Ther; 2012 Sep; 50(9):683-9. PubMed ID: 22735459
[TBL] [Abstract][Full Text] [Related]
3. Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects.
Li Z; Wang G; Wang LS; Zhang W; Tan ZR; Fan L; Chen BL; Li Q; Liu J; Tu JH; Hu DL; Liu ZQ; Zhou HH
Xenobiotica; 2009 Oct; 39(10):788-93. PubMed ID: 19604036
[TBL] [Abstract][Full Text] [Related]
4. Allele and genotype frequencies of CYP2C9 in a Korean population.
Bae JW; Kim HK; Kim JH; Yang SI; Kim MJ; Jang CG; Park YS; Lee SY
Br J Clin Pharmacol; 2005 Oct; 60(4):418-22. PubMed ID: 16187974
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.
Yasar U; Forslund-Bergengren C; Tybring G; Dorado P; Llerena A; Sjöqvist F; Eliasson E; Dahl ML
Clin Pharmacol Ther; 2002 Jan; 71(1):89-98. PubMed ID: 11823761
[TBL] [Abstract][Full Text] [Related]
6. Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics.
Lee HW; Lim MS; Lee J; Jegal MY; Kim DW; Lee WK; Jang IJ; Shin JG; Yoon YR
J Clin Pharm Ther; 2012 Feb; 37(1):105-11. PubMed ID: 21208246
[TBL] [Abstract][Full Text] [Related]
7. CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects.
Choi CI; Kim MJ; Chung EK; Lee HI; Jang CG; Bae JW; Lee SY
Eur J Clin Pharmacol; 2012 Feb; 68(2):149-54. PubMed ID: 21842338
[TBL] [Abstract][Full Text] [Related]
8. Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers.
Han Y; Guo D; Chen Y; Chen Y; Tan ZR; Zhou HH
Eur J Clin Pharmacol; 2009 Jun; 65(6):585-91. PubMed ID: 19221727
[TBL] [Abstract][Full Text] [Related]
9. Allele and genotype frequency of CYP2C9 in Tamilnadu population.
Adithan C; Gerard N; Vasu S; Balakrishnan R; Shashindran CH; Krishnamoorthy R
Eur J Clin Pharmacol; 2003 Nov; 59(8-9):707-9. PubMed ID: 14504850
[TBL] [Abstract][Full Text] [Related]
10. Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes.
Hatta FH; Teh LK; Helldén A; Hellgren KE; Roh HK; Salleh MZ; Aklillu E; Bertilsson L
Eur J Clin Pharmacol; 2012 Jul; 68(7):1033-42. PubMed ID: 22294058
[TBL] [Abstract][Full Text] [Related]
11. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.
Lee CR; Pieper JA; Hinderliter AL; Blaisdell JA; Goldstein JA
Pharmacotherapy; 2003 Jun; 23(6):720-5. PubMed ID: 12820813
[TBL] [Abstract][Full Text] [Related]
12. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174.
Kaukonen KM; Olkkola KT; Neuvonen PJ
Eur J Clin Pharmacol; 1998 Feb; 53(6):445-9. PubMed ID: 9551703
[TBL] [Abstract][Full Text] [Related]
13. Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects.
Huang HX; Wu H; Zhao Y; Zhou T; Ai X; Dong Y; Zhang Y; Lai Y
Xenobiotica; 2021 May; 51(5):616-623. PubMed ID: 33509019
[TBL] [Abstract][Full Text] [Related]
14. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects.
Sekino K; Kubota T; Okada Y; Yamada Y; Yamamoto K; Horiuchi R; Kimura K; Iga T
Eur J Clin Pharmacol; 2003 Nov; 59(8-9):589-92. PubMed ID: 14504849
[TBL] [Abstract][Full Text] [Related]
15. Allele and genotype frequencies of CYP2C9 within an Iranian population (Mazandaran).
Hashemi-Soteh SM; Shahabi-Majd N; Gholizadeh AR; Shiran MR
Genet Test Mol Biomarkers; 2012 Jul; 16(7):817-21. PubMed ID: 22288731
[TBL] [Abstract][Full Text] [Related]
16. CYP2C9 genetic variants and losartan oxidation in a Turkish population.
Babaoglu MO; Yasar U; Sandberg M; Eliasson E; Dahl ML; Kayaalp SO; Bozkurt A
Eur J Clin Pharmacol; 2004 Jul; 60(5):337-42. PubMed ID: 15197523
[TBL] [Abstract][Full Text] [Related]
17. [Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects].
Zhang YF; Chen XY; Guo YJ; Si DY; Zhou H; Zhong DF
Yao Xue Xue Bao; 2005 Sep; 40(9):796-9. PubMed ID: 16342679
[TBL] [Abstract][Full Text] [Related]
18. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.
Hamdy SI; Hiratsuka M; Narahara K; El-Enany M; Moursi N; Ahmed MS; Mizugaki M
Br J Clin Pharmacol; 2002 Jun; 53(6):596-603. PubMed ID: 12047484
[TBL] [Abstract][Full Text] [Related]
19. Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans.
Allabi AC; Gala JL; Horsmans Y; Babaoglu MO; Bozkurt A; Heusterspreute M; Yasar U
Clin Pharmacol Ther; 2004 Aug; 76(2):113-8. PubMed ID: 15289788
[TBL] [Abstract][Full Text] [Related]
20. P450 (Cytochrome) Oxidoreductase Gene (POR) Common Variant (POR*28) Significantly Alters CYP2C9 Activity in Swedish, But Not in Korean Healthy Subjects.
Hatta FH; Aklillu E
OMICS; 2015 Dec; 19(12):777-81. PubMed ID: 26669712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
